Amputation, one of worse prognostic variables

Original title: Lower Extremity Amputation: Factors Associated With Mortality or Contralateral Amputation Reference: Samir K. Shah, et; al. Vascular and Endovascular Surgery 2013:47 (8):608-613.

Peripheral vascular disease is associated with trophic injuries with tissue lose, often leading to amputation, of which about 50 % were major amputations. 454 amputations in 391 patients were analyzed, 63 were contralateral. Most of the patients have received prior treatment before amputation, which generally was angioplasty procedure.

The amputation rate was 70% transtibial and 30% transfemoral. Mortality at 30 days after amputation was 9.2 %, and after 1, 2 and 5 years revealed 30%, 40% and 56 % respectively, with an average survival of 25.4 months. The variables associated with mortality were age, dialysis, high cardiac risk and transfemoral or transtibial amputation. The need of dialysis and high cardiac risk were associated with contralateral amputation. The only variable that produced protection against death was the contralateral limb intervention. Survival free of contralateral amputation – at 1, 2 and 5 years was 60 %, 49 % and 33 % respectively. The following factors with high risk were associated with contralateral amputation:  Age and moderate or high cardiac risk, having the intervention in that limb a protective effect.

Conclusion

Patients with advanced peripheral vascular disease requiring amputation of one lower limb have a decrease in survival and a high rate of amputation of the contralateral limb. Age and dialysis are factors that predispose to amputation. These data favor the strategies to improve limb preservation. 

Comment

Amputation is associated with poor short-term outcome and increases the risk of repeated in the contralateral limb. It is necessary to optimize medical treatment and education of patients and their relatives in order to prevent or avoid trophic lesions. It is very important before performing angiographic studies or try limb revascularization in the best possible way, once or several times before making the final decision. 

Courtesy of Carlos Fava MD
Interventional Cardiologist
Favaloro Foundation
Argentina

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...